Merck Sharp & Dohme (MSD) has increased the production of its measles vaccine in the US to meet a rise in demand following an outbreak.

The drugmaker is one of the only suppliers of measles vaccines in the US, noted Reuters. Merck said that the increase in demand was evident but has not led to a significant increase in distribution.

This year’s measles outbreak is said to be the largest since 1994. The disease was declared eliminated in 2000.

Statistics from the US Centers for Disease Control and Prevention (CDC) show that nearly 704 individuals have been affected in 22 states from 1 January to 26 April.

Merck believes that it will be able to meet this growing demand.

“We’ve always been able to surge capacity, and we feel confident about our ability to do so in the US.”

Merck chief marketing officer Mike Nally said: “As measles outbreaks have occurred in different parts of the world over the last few decades, we’ve always been able to surge capacity, and we feel confident about our ability to do so in the US.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company recently announced financial results for the first quarter of this year, reporting $10.8bn in global sales, a rise of 8% compared with the same quarter of 2018. This was followed by a securities filing, which disclosed plans to restructure the company’s manufacturing and supply network in a bid to mitigate its global real estate footprint.

Expected to be completed by the end of 2023, the restructuring is estimated to incur pre-tax costs of between $800m and $1.2bn.

Merck said that nearly 55% of the cumulative pre-tax costs will be in cash for employee separation expense and facility shutdowns, while the remaining 45% will be towards “accelerated depreciation of facilities to be closed or divested.”